Articles related to PEDIATRIC INFECTIOUS DISEASES

“We saw the same inclusion bodies targeted in every tissue sample spanning five decades and two continents, which shows that we are dealing with one predominant virus causing Kawasaki disease.” – Anne Rowley, MD

Capvaxive was noninferior to PPSV23 for each of the 12 serotypes present between the 2 vaccines and superior for each of the 9 serotypes unique to Capvaxive.

The guidelines discourage bag specimen cultures due to contamination risk and recommend catheterized collection for accurate diagnosis in young children.

Age-specific inflammatory marker thresholds and staged evaluation permit safe outpatient management of select febrile infants 22-90 days old, while maintaining full evaluation and treatment for higher-risk infants under 21 days.

Routine vaccination of infants under 8.5 months of age may lead to blunted MeV-specific antibody responses to subsequent MMR vaccination. Early MMR vaccination should only be considered during measles outbreaks or in other situations of increased risk of MeV infection.

The guidelines introduce a significant shift in treatment duration, suggesting 10-14 days may be sufficient for uncomplicated cases showing rapid clinical improvement, challenging traditional 21-28 day courses.